Open access

Circulating protein profiling identifies prognostic biomarkers in amyotrophic lateral Sclerosis

H. Klimovski M. Weinreich A. Strange I. Magen E. Alhathli Y. Cohen D. Melamed-Kadosh D. Lester A. Taylor Y. Zhou T. Ziv B. Abramovich A. Subramanian E. Perlson V. Drory A. Admon P. Shaw A. Malaspina M. Turner K. Talbot J. Cooper-Knock A. Thompson E. Hornstein

Jul 2026 · medRxiv · 0 citations

Medicine

TL;DR

The utility of multiple proteins reflecting diverse biological pathways in refining survival stratification is indicates the utility of multiple proteins reflecting diverse biological pathways in refining survival stratification and highlights systemic factors in ALS progression.

DOI Semantic Scholar

Read PDF

Similar papers

Open access Sep 2026

Molecular subgroups of ALS patients with distinct survival outcomes identified through plasma proteomics

Cell-type enrichment analysis indicating a broad cellular origin of the circulating proteome, with contributions from nervous system cells, vascular cells, immune cells, and muscle cells, highlights the potential of plasma proteomics for clinically meaningful patient stratification in ALS.

I. Aksoylu, L. Azizi, L. OÌijerstedt et al. · medRxiv · 0 citations

Sep 2026

Evaluation of potential serum biomarkers for individuals at risk of multiple sclerosis highlights SPP1.

Investigating whether alterations in six previously MS-associated biomarkers are detectable and associated with underlying genetic susceptibility in two independent sample collections suggest that several circulating proteins recently proposed as MS biomarkers are not robust tools to distinguish MS from healthy individ...

Kristin Mounts, Yun-Duo Liu, Masashi Fujita et al. · Multiple Sclerosis and Relat... · 0 citations

Open access Sep 2026

Decreased cerebrospinal fluid TNFRSF8 (sCD30) confirmed as a biomarker of Huntington’s disease progression

The results indicate and confirm that TNFRSF8 is highly dysregulated in HDGECs and also tracks clinical disease progression, and may be a promising potential target for DMTs.

Helga Maria Grétarsdóttir, Janet L. Cunningham, A. Rasmusson et al. · Journal of Neurology · 0 citations

Open access Aug 2026

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

It is suggested that serum GFAP may serve as a biomarker for personalized risk stratification and treatment monitoring and as a screening tool to reduce cohort size in clinical trials targeting MS progression.

M. Einsiedler, S. Sandgren, S. Schaedelin et al. · JAMA Neurology · 0 citations

Open access Sep 2026

Integrated microRNA–protein plasma biomarkers improve discrimination of multiple system atrophy from Parkinson’s disease

Findings show that a non-invasive plasma multi-analyte panel can differentiate MSA from PD with clinically meaningful accuracy, and support prospective validation in larger cohorts.

Hsiang-Hsuan Lin-Wang, Yi-Tzang Tsai, Jing-Wen Huang et al. · npj Parkinson's Disease · 0 citations

Sep 2026

Proteomic and Functional Signatures of Phenoconversion in Presymptomatic Amyotrophic Lateral Sclerosis.

ALS exhibits a measurable molecular prodrome detectable in blood years before diagnosis, and integrated proteomic and genetic profiling may support early identification and trial enrichment strategies.

S. Lehrer, P. Rheinstein · Journal of Clinical Neuromus... · 0 citations